Docoh
Loading...

LABP Landos Biopharma

GRANT
Utility
Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
14 Dec 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 16 Nov 18
GRANT
Utility
PLXDC2 ligands
23 Nov 21
Provided are compounds that target plexin domain containing 2 (PLXDC2).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 25 Mar 21
APP
Utility
Lanthionine C-like Protein 2 Ligands, Cells Prepared Therewith, and Therapies Using Same
18 Nov 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 2 Aug 21
APP
Utility
NLRX1 Ligands
7 Oct 21
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 17 Jun 21
APP
Utility
PLXDC2 Ligands
7 Oct 21
Provided are compounds that target plexin domain containing 2 (PLXDC2).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 25 Mar 21
GRANT
Utility
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
14 Sep 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 18 Dec 20
GRANT
Utility
NLRX1 ligands
20 Jul 21
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 1 May 20
APP
Utility
Lanthionine C-like Protein 2 Ligands, Cells Prepared Therewith, and Therapies Using Same
24 Jun 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 18 Dec 20
APP
Utility
Lanthionine Synthetase C-like 2-BASED Therapeutics
18 Feb 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 20 Oct 20
GRANT
Utility
Lanthionine synthetase C-like 2-based therapeutics
30 Nov 20
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 3 May 20
APP
Utility
Lanthionine Synthetase C-like 2-BASED Therapeutics
19 Aug 20
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 3 May 20
APP
Utility
NLRX1 Ligands
12 Aug 20
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 30 Apr 20
GRANT
Utility
Lanthionine synthetase C-like 2-based therapeutics
15 Jun 20
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 14 Oct 19
GRANT
Utility
NLRX1 ligands
8 Jun 20
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 1 Jul 19
APP
Utility
Lanthionine Synthetase C-like 2-BASED Therapeutics
12 Feb 20
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 14 Oct 19
APP
Utility
NLRX1 Ligands
8 Jan 20
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 1 Jul 19
GRANT
Utility
Lanthionine synthetase C-like 2-based therapeutics
2 Dec 19
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 19 Dec 18
GRANT
Utility
NLRX1 ligands
25 Nov 19
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 6 Feb 19
  • 1
Patents are sorted by USPTO publication date, most recent first